PATENT CLAIM ANALYSIS

Application Number: 16227132
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["544", "283000"]

Abstract:
The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

Claim (Index 28):
The compound of  claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R A  is independently selected from C 1-6  alkyl, OR a1 , C(O)R b1 , NR c1 R d1 , and S(O) 2 R b1 ; wherein said C 1-6  alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy 1 , Cy 1 -C 1-4  alkyl, halo, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 1-6  haloalkyl, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , C(\u2550NR e1 )NR c1 R d1 , NR c1 C(\u2550NR e1 )NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , NR c1 C(O)NR c1 R d1 , NR c1 S(O)R b1 , NR c1 S(O) 2 R b1 , NR c1 S(O) 2 NR c1 R d1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 , and S(O) 2 NR c1 R d1 .

Metadata:
- Claim Count in Document: 87.0
- Percentile: 98.0
- Lexical Diversity: 1.2
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15166380', '12270135', '14465910', '16308739', '15521202']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8168000930134152
- 35 USC 102 Novelty (BERT): 0.5162802332748785
- Combined Prediction Score: 0.7867481070395616
- Mean Citation Score: 326.669524
- Max Citation Score: 338.04504
- Similarity Product: 310.5645101943112

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test